ReviewPharmaceutics2026
Reimagining Antimicrobial Drug Delivery: Spatiotemporally Adaptive Therapeutics for Biofilm-Associated Infections and Antimicrobial Resistance.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial therapy may fail even when an agent is intrinsically active if effective drug exposure is not achieved at the site of infection at the appropriate time. This challenge is particularly important in biofilm-associated infections and infections caused by drug-resistant pathogens, where biological barriers, spatial heterogeneity, and changing microbial states can limit treatment effectiveness. This narrative review examines advanced antimicrobial delivery from a problem-oriented perspective, focusing on the therapeutic challenges that delivery systems are designed to address. It explores how antimicrobial exposure can be aligned with the location, biological state, and changing course of infection. The review examines the biological and pharmacological barriers that restrict antimicrobial activity and discusses strategies designed to improve drug access, retention, release, and local activity. Localized delivery, responsive and externally triggered systems, controlled and sequential delivery, and multimodal therapy are considered as implementation strategies within a common spatiotemporal framework. Particular attention is given to the relationship between formulation design, local drug exposure, biological response, and therapeutic outcome. The review further examines the factors that determine whether a technically promising system has a realistic clinical role, including safety, reproducibility, manufacturability, model relevance, and demonstrable benefits over simpler approaches. Future priorities are considered from a clinically defined perspective. Overall, the review argues that the value of advanced antimicrobial delivery lies not in carrier complexity alone, but in its capacity to provide a measurable and reproducible therapeutic advantage for a clearly defined infection setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.